Therapeutic Targeting of the Cancer-Specific Cell Surface Biomarker nfP2X7
نویسندگان
چکیده
منابع مشابه
Therapeutic Targeting of the Cancer-Specific Cell Surface Biomarker nfP2X7
Citation: Barden JA, Gidley-Baird A, Teh LC, Rajasekariah GH, Pedersen J, et al. (2016) Therapeutic Targeting of the Cancer-Specific Cell Surface Biomarker nfP2X7. J Clin Cell Immunol 7: 432. doi:10.4172/2155-9899.1000432 Copyright: © 2016 Barden JA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, dis...
متن کاملCell-specific targeting by engineered M13 bacteriophage expressing VEGFR2 nanobody
Objective(s): Filamentous bacteriophage M13 was genetically engineered to specifically target mammalian cells for gene delivery purpose. Materials and Methods: A vascular endothelial growth factor receptor 2 (VEGFR2)-specific nanobody was genetically fused to the capsid gene III of M13 bacteriophage (pHEN4/3VGR19). A mammalian expression construct containing Cop-green fluorescent protein (Cop-G...
متن کاملBack to the Future: Therapeutic Targeting of Cancer Cell Metabolism.
An introduction by Raymond Gilmour (Discovery Oncology Research, Lilly Research Laboratories, USA) and Susana Velasco (Cell Signaling Therapies, Centro Nacional de Investigaciones Oncológicas (CNIO), Spain) notes that with new tools and technologies in place, cancer metabolism has become an area of renewed focus for both basic research and drug discovery efforts. The ability to link genetics wi...
متن کاملTherapeutic Exploitation of Targeting Programmed Cell Death for Cervical Cancer
Programmed cell death (PCD) is a basic biological phenomenon that plays an important role during development, preservation of tissue homeostasis, and elimination of damaged cells. Several nomenclature systems have been proposed to classify PCD. One widely accepted system describes three major morphologies of programmed cell death, and classifies PCD as type I, apoptosis; type II, autophagy; and...
متن کاملCan Prostate Specific Antigen Be Used as New Biomarker for Early Diagnosis of Breast Cancer?
Introduction: As a glycoprotein, Plasma Prostate-Specific Antigen (PSA) is mainly produced by prostate epithelial cells and is used as a major diagnostic tool for prostate cancer. A group of researchers relate the elevated number of estrogen receptors in breast cancer samples to the over-production of PSA in this type of cancer. Therefore, the present study aimed to determine the participants' ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Clinical & Cellular Immunology
سال: 2016
ISSN: 2155-9899
DOI: 10.4172/2155-9899.1000432